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Crush injuries and crush syndrome – a review.
Part 2: the local injury
Nikolas A Jagodzinski, Charitha Weerasinghe and Keith Porter
Crush injuries can occur in considerable numbers following natural disasters or acts of
war and terrorism. They can also occur sporadically after industrial accidents or
following periods of unconsciousness from drug intoxication, anaesthesia, trauma or
cerebral events. A common pathophysiological pathway has been elucidated over the
last century describing traumatic rhabdomyolysis leading to myoglobinuric acute renal
failure and a systemic ‘crush syndrome’ affecting many organ systems. If left
unrecognised or untreated then mortality rates are high. If treatment is commenced
early and the systemic effects are minimised then patients are often faced with
significant morbidity from the crushed limbs themselves. We have performed a
thorough review of the English language literature from 1940–2009 investigating crush
injuries and crush syndrome and present a comprehensive, two-part summary. Part 1:
The systemic injury, we concentrate on the systemic crush syndrome. We determine
the pathophysiology, clinical and prognostic indicators and treatment options such as
forced alkaline diuresis, mannitol therapy, dialysis and haemofiltration. We discuss
more controversial treatment options such as allopurinol, potassium binders, calcium
therapy and other diuretics. We also discuss the specific management issues of the
secondary ‘renal disaster’ that can occur following earthquakes and other mass
disasters. Part 2: The local injury, we look in more detail at the pathophysiology of
skeletal muscle damage following crush injuries and discuss how to minimise
morbidity by salvaging limb function. In particular we discuss the controversies
surrounding fasciotomy of crushed limbs and compare surgical management with
conservative techniques such as mannitol therapy, hyperbaric oxygen therapy, topical
negative pressure therapy and a novel topical treatment called gastric pentadecapep-
tide BPC 157.
Key words: crush injury; fasciotomy; hyperbaric oxygen; mannitol; topical negative
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Introduction
Crush injury is the term given to the localized tissue
injury sustained when a crush pressure is applied to
a limb (Reis and Michaelson, 1986). Crush
syndrome describes the systemic complications
that occur following a crush injury to a limb.
Traumatic rhabdomyolysis causes efflux of cellular
components such as potassium and myoglobin into
the systemic circulation, leading to a spectrum of
life-threatening conditions including cardiomyopa-
thy and acute renal failure (ARF) as discussed in
Part 1: The Systemic Injury (Mubarak and Owen,
1975).
Crush injuries occur most commonly after natu-
ral or man-made disasters such as earthquakes,
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mining and industrial accidents and in warzones,
where falling debris can crush hundreds of patients
at once. (Smith and Greaves, 2003). Research from
around the world over the last century has devel-
oped our knowledge of the pathophysiology and
management of the systemic effects of the crush
syndrome. It is well established that it is inherently
preventable and reversible if intensive treatment is
started early. Mortality rates can be dramatically
reduced if appropriate personnel are involved and
protocols are followed (Michaelson, 1992; Oda
et al., 1997).
As more people are surviving the systemic man-
ifestations of crush syndrome, clinicians are now
faced with increasing morbidity rates from the
crushed limbs themselves. The body’s entire
volume of interstitial fluid (around 12L in an
average 75 kg man) can shift intracellularly when
myocytes are crushed. This inevitably causes limbs
to swell massively and an ensuing compartment
syndrome can reduce the functional recovery of the
limb (Quan et al., 2009). Fasciotomy and radical
debridement has been the gold standard of treat-
ment for compartment syndrome for decades, but
complicating a crush injury with a surgical wound
has proved to cause severe sepsis and death
(Michaelson et al., 1984; Michaelson, 1992; Reis
and Better, 2005).
We have performed a review of all available
literature in the English language from Medline,
Embase, Ovid and Cinahl from 1950 to July 2009
searching for ‘crush syndrome,’ ‘crush injury’ and
‘crush injuries’ in the title. We have also reviewed
the British Nursing Index, the Database of
Abstracts of Reviews of Effects and the Health
Technology Assessment Database with the same
search terms. Our search produced 1371 articles of
which 624 were duplicates. In Part 1, we reviewed
the pathophysiology of the systemic effects of
crush injuries in order to determine the best
methods of assessment, treatment and prevention.
Our aims in Part 2 are to look in more detail at the
localized injury to crushed limbs and what treat-
ment options are available to minimize morbidity.
We excluded articles relating to nerve crushes and
the ‘double crush syndrome’ and analysed the
remaining 396 abstracts for relevance. We have
included reviews of 111 articles in Part 1 and 94
articles in Part 2, including appropriate cross-
references.
In Part 2: The Local Injury, we illustrate the
pathophysiology of local muscle crush injury, and
the latest evidence on how to optimise long-term
functional recovery. We illustrate the controversial
role of fasciotomy for compartment syndrome
(Sever et al., 2002) and highlight novel therapies
such as mannitol, hyperbaric oxygen, topical neg-
ative pressure therapy and the newly discovered
gastric pentadecapeptide, BPC 157, as possible
conservative adjuncts, or even alternatives.
Pathophysiology
Muscle damage occurs at three distinct stages: at the
time of the initial mechanical crushing force, during
the period of ischaemia and during the period of
reperfusion (Walker et al., 1987). The time from
injury to cell death varies with the compressing
force involved. Skeletal muscle can tolerate ischae-
mia for up to 2 h without permanent injury. From
2–4 h, some reversible cell damage occurs and by
6 h irreversible tissue necrosis generally sets in
(Malinoski et al., 2004). Compressing peripheral
nerves rapidly causes a neurapraxia. More pro-
longed or severe crushing forces commonly cause
axonotmesis, but neurotmesis only usually occurs if
the initial impact causes traction and nerve rupture
(Campbell, 2009).
Ischaemic and pressure-stretch myopathy
It has been hypothesized that ischaemia is the
primary instigator of local muscle damage following
crush injuries (Jarvinen et al., 2005). As a crushing
force causes obliteration of the blood supply,
anaerobic respiration of myocytes leads to less
adenosine triphosphate (ATP) being produced.
Cationic pump activity at the sarcolemmal mem-
brane decreases in these ischaemic conditions,
leading to failure of cell homeostatic mechanisms,
and eventual cell death and necrosis. However,
studies have shown that although skeletal muscle
tissue can survive circulatory ischaemia for 4 h, the
mechanical force sustained in crushing, along with
ischaemia, causes skeletal muscle death in only 1 h
(Reis and Michaelson, 1986).
The initial insult is now thought to be secondary
to a pressure-stretch myopathy. Stretching of the
cell membrane during application of crush pressure
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allows sodium, chloride, calcium and water to
diffuse into cells down their electrochemical gradi-
ent. These ions cannot be extruded quickly enough,
despite homeostatic pumps working to maximal
capacity whilst using up available ATP. The cell
now becomes more prone to a secondary ischaemic
insult, due to lack of ATP (Better et al., 1990).
Influx of ions and water from the interstitial
compartment causes myocytes to swell. The osmotic
gradient from the interstitial compartment, in turn,
draws fluid from the intravascular compartment
causing profound hypovolaemia and shock. Within
the unrelenting confines of the fascial compartment,
this interstitial and intracellular oedema creates a
compartment syndrome of muscle tamponade,
myoneural ischaemia and rhabdomyonecrosis
(Better et al., 2003).
Intracellular calcium accumulation activates
autolytic processes and decreases cellular respira-
tion, further damaging the cell (Better et al., 2003).
The reperfusion syndrome
Studies of enzyme release suggest that most damage
to myocytes occurs during the reperfusion stage
rather than the ischaemic stage (Presta and
Ragnotti, 1981). Several mechanisms have been
postulated to contribute to the ‘reperfusion
syndrome.’
It is known that xanthine dehydrogenase, is
proteolytically cleaved to xanthine oxidase during
the ischaemic stage of muscle injury. Odeh’s ‘oxygen
paradox’ theory proposes that reperfusion of
ischaemic tissue then provides oxygen as a substrate
for xanthine oxidase and other enzymes to produce
hydroxyl free-radicals (Odeh, 1991a). These reactive
oxygen metabolites directly damage muscle cell
membranes by lipid peroxidation (Linas et al.,
1990). Free-radicals initiate a chain reaction of
further free-radical production explaining the rapid
propagation of myocyte death, and the subsequent
damage to other body organs as shown in Part 1:
The Systemic Injury (Braunwald and Kloner, 1985;
Walker et al., 1987; Blaisdell, 2002; Krost et al.,
2008). Reperfusion of ischaemic kidneys and heart
can cause secondary damage to their vasculature by
similar mechanisms predisposing them to a double
hit of free-radical attack (Odeh, 1991a).
In canine models it has been shown that the
microvasculature of skeletal muscle is also damaged
by free-radicals. The increased permeability causes a
vicious cycle of worsening oedema and compart-
ment syndrome (Korthuis et al., 1985). To support
this theory, studies have shown that free radical
scavengers such as mannitol, superoxide dismutase
and allopurinol, when administered before, or very
early on in limb reperfusion, can drastically reduce
the extent of muscle necrosis (Walker et al., 1987).
We have discussed the clinical use of these agents to
treat crushed patients in Part1: The Systemic Injury.
Odeh also proposes the ‘calcium paradox’ theory
of tissue damage following reperfusion (Odeh,
1991a). ATP driven sodium-potassium pumps of
myocytes fail in the acidotic conditions of anaerobic
respiration. Sodium–hydrogen exchange leads to an
intracellular accumulation of sodium. Sodium–
calcium exchange pumps survive this ischaemic
period and sodium is then rapidly exchanged for
calcium on reperfusion (Braunwald and Kloner,
1985). Clinically, the influx of calcium intracellu-
larly causes muscle contractures and a profound
hypocalcaemia.
Calcium impairs cellular function by several
mechanisms. Firstly, it’s accumulation in mitochon-
dria further reduces ATP formation by interfering
with the processes of respiration. Secondly, it
activates phospholipase A2 producing lysophospho-
lipids, leukotreines and prostaglandins that cause
autophagy and necrotic cell death (Lemasters et al.,
1998). Thirdly, calcium acts as a catalyst for
xanthine oxidase conversion from its precursor,
accelerating the ‘oxygen paradox’ and free-radical
propagation.
Evidence for calcium’s role in reperfusion injury
is supported by experiments where calcium influx
blockers such as amiloride are administered before
the crushing force is released. Amiloride, a
potassium-sparing diuretic inhibits sodium–hydro-
gen and sodium–calcium exchange in many tissues.
The marked reduction in intracellular calcium
improves contractile and metabolic recovery
during postischaemic reperfusion (Prendes et al.,
2008). Benzamil is an analogue of amiloride that has
an even more potent ability to block sodium-
calcium exchange and is more protective against
the ‘calcium paradox’ than amiloride.
The published responses to Odeh’s article suggest
these agents should be contra-indicated in the
treatment of crush injuries due to the possible
aggravation of hypotension and hyperkalaemia.
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Odeh’s retort was that, if these agents are admin-
istered before reperfusion takes place, then myocyte
damage is minimised to such an extent that the
systemic effects of reperfusion, including hyperka-
laemia, are also minimal (Odeh, 1991b). Aggressive
volume replacement and administration of potas-
sium binders can also help prevent these complica-
tions (Screaton et al., 1991).
Treatment options for crushed limbs
If a patient survives the systemic effects of a crush
syndrome, he can then be faced with high rates of
morbidity from the crushed limb itself. There is
widespread debate as how best to manage crushed
limbs.
Limb amputation
If a crushed limb is trapped and preventing extri-
cation then amputation at scene should be consid-
ered a life-saving measure (Stewart et al., 1979;
Stewart, 1999). In a similar way to tourniquet
application, limb amputation before release of the
crushing force may prevent the sequelae of the
reperfusion syndrome and minimise the systemic
insult (Stewart et al., 1979). In order to prevent
morbidity from amputation, however, all attempts
should be made to preserve crushed limbs. As
discussed in Part 1, the systemic insult is treatable
and preventable with adequate fluid resuscitation
and appropriate intensive therapy. Advances in
reconstructive surgical techniques can restore some
limb function (Porter and Greaves, 2003).
Once patients have been resuscitated, limbs may
need fasciotomies, radical debridement or amputa-
tion if deemed unsalvageable, especially in open
injuries or in patients deteriorating despite resusci-
tative measures (Cossio, 1977). In Bywaters and
Beall’s benchmark paper in 1941 they recognised
that amputation at 36 h post injury was not
adequately early to prevent deterioration and
death from ARF (Bywaters and Beall, 1941).
Santangelo et al. proposed that a creatine : creati-
nine ratio greater than 1 : 10 was a reliable index of
cellular necrosis in this situation and may indicate
which patients would benefit from prompt, poten-
tially life-saving, amputation (Santangelo et al.,
1982).
Compartment syndrome and the role of fasciotomy
Compartment syndrome of a limb can occur
following any mechanism of injury including
muscle contusions, sprains and burns, but more
commonly following fractures, either open or closed
(Hope and McQueen, 2004). McQueen et al. dem-
onstrated that crush injuries caused 8% of all
compartment syndromes around Edinburgh
over an 8-year period up to 1999 (McQueen et al.,
2000). When there is no underlying fracture, crush
injuries are implicated in 21% of compartment
syndromes. Compartment syndromes develop fol-
lowing most crush injuries of significant force and
duration. There is a wide spectrum of incidences
through the literature. For example, in one study
of earthquake victims where 75 people were
crushed, 43 developed compartment syndrome
(Kurt et al., 2003).
Compartment syndrome is an acute surgical
emergency. Inflammation and oedema following
injury to a limb causes swelling and increased
pressure within the enclosed fascial compartments.
Microvasculature within skeletal muscle is com-
pressed causing painful ischaemia and rhabdomy-
olysis. Lymphatic and venous drainage are next to
be compressed causing venous congestion. A cycle
of progressive swelling and increasing pressure
ensues with subsequent compression of nerves and
then arteries (Matsen and Krugmire, 1978; Elliott
and Johnstone, 2003; Krost et al., 2004). If a
compartment syndrome remains untreated, the
sequelae can be catastrophic including neurological
deficit, muscle necrosis, ischaemic contracture,
infection and delayed union of fractures. Also,
compartment syndromes from any cause can inde-
pendently lead to ARF and a systemic crush
syndrome (Elliott and Johnstone, 2003).
Diagnosis of compartment syndrome is often
difficult but a high index of clinical suspicion should
be adopted following any trauma to a limb.
Objective measuring tools such as manometers,
near infrared spectroscopy, magnetic resonance
imaging, perfusion scintigraphy and laser doppler
flowmetry can all aid diagnosis but clinical judge-
ment should prevail (Elliott and Johnstone, 2003).
Emergency fasciotomy is the gold-standard treat-
ment. Compartmental pressures are released and
perfusion is restored to skeletal muscle where
arteries remain intact. Surviving muscle is salvaged
allowing for a degree of function to be retained.
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Delay to fasciotomy is strongly related to compli-
cation rates (Sheridan and Matsen, 1976).
There is widespread agreement that early, exten-
sive fasciotomy with decompression of all compart-
ments within a limb is the treatment of choice for
compartment syndrome. (Brown and Nicholls,
1977; Matsen et al., 1980; McQueen et al., 1996;
Pelligrini et al., 1996). However, some controversy
exists as to the role of fasciotomy in the manage-
ment of compartment syndromes that develop
specifically following crush injuries. The majority
of authors in the historical literature believe that the
similarities between crush injury and compartment
syndrome call for the same treatment that is, early
fasciotomy (Santangelo et al., 1982). Various other
reports suggest that fasciotomies following crush
injuries do not give good results and are directly
related to mortality rates (Michaelson et al., 1984;
Michaelson, 1992; Reis and Better, 2005).
If fasciotomies are performed on a crushed limb,
it is important to note that crushed, dead muscle
appears pink and bleeds profusely giving the false
impression that it remains alive (Michaelson, 1992).
Profuse oozing is very difficult to control surgically
due to loss of capillary tone from injury and an
acidaemic environment. Michaelson, Reis and
Better propose that all muscle that is unresponsive
to mechanical or electrical stimulation, regardless of
its appearance, should be debrided at the time of the
first fasciotomy. Aggressive debridement minimises
blood loss, coagulopathies and sepsis (Reis and
Michaelson, 1986; Michaelson, 1992; Reis and
Better, 2005). Their various reports from Haifa,
Israel, suggest:
(1) Open crush injuries should be treated in the
same manner as any traumatic wound, with
early extensive debridement of devitalised tissue
and fasciotomy if indicated.
(2) Closed crush injuries with absent pulses should
also be urgently decompressed by fasciotomy in
order to salvage the limb distally.
(3) There is a significantly higher rate of sepsis and
mortality following closed lower limb crush
injuries treated with fasciotomy compared to
patients treated conservatively. They propose
that fasciotomy should be contra-indicated in a
closed crush injury if distal pulses are present.
(4) The consequences of limb fibrosis, paralysis and
contractures should be accepted and dealt with
at a later date by reconstructive surgery,
arthrodesis and amputation when necessary.
(5) Muscle that has been crushed for a significant
period of time is already dead and salvage is
futile. Converting a closed injury to an open
wound in such circumstances enables bacteria
to access the rich culture medium of necrotic
muscle.
(6) Recurrent bleeding from a fasciotomy wound
can also complicate the crush syndrome and
complicate dialysis for ARF.
(7) Initial debridements are inevitably incomplete
and the requirement for repeated debridements
can put a strain on surgical service provision,
especially in a mass disaster zone where crush
injuries present in epidemic proportions.
Morbidity from fasciotomy wounds can be
extremely high with patients presenting with pain,
paraesthesia, dry, scaly skin, pruritis, tendon teth-
ering and muscle herniation. The appearance of
large scars can cause psychological trauma to some
patients as well (Fitzgerald et al., 2000).
Huang et al. report high infection and amputa-
tion rates after fasciotomy for crush injuries during
the Chi-Chi earthquake in China (Huang et al.,
2002). Lin’s experiences in Taiwan concurs with
these opinions that, despite textbook teaching of
fasciotomy for compartment syndromes, it signifi-
cantly increases the risk of life-threatening infec-
tions and worsening of the systemic sequelae of
crush syndrome (Pelligrini et al., 1996; Lin, 2003a,
2003b, 2005; Reis and Better, 2005).
Experience of treating crush injuries non-
surgically shows that sensation returns after the
acute phase numbness, accompanied by transient
paraesthesia and severe pain requiring continuous
analgesia (Reis and Michaelson, 1986). One-year
follow-up of these patients demonstrated that they
could all walk unaided and without disability but
had some residual stiffness and weakness. In com-
parison, the patients that underwent fasciotomy and
debridement also had return of pain and touch
sensations but their limbs were motionless. In this
situation, arthrodesis is believed superior to ampu-
tation as the leg can function as a living prosthesis
(Michaelson, 1992). Amputation of a limb should
only be performed if infection is endangering the
patient’s life.
The mechanisms behind crushed muscle recover-
ing so well following non-surgical treatment are not
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well understood. The best explanation is that there
are some fibres within crushed muscle that escape
damage and subsequently recuperate (Brown and
Nicholls, 1977). However, logic would dictate that
early surgical decompression of these surviving
myocytes should improve their outcome if infection
is avoided.
Sever et al. (2002) reviewed victims with renal
problems following the Marmara earthquake in
Turkey in 1999 where 397 fasciotomies were per-
formed on 323 victims and 316 were treated non-
surgically. Twenty five percent of the fasciotomized
patients developed sepsis compared with only 13%
of the non-fasciotomized victims (p50.001).
Dialysis was performed on 83.9% of fasciotomized
victims compared with 65.2% of the non-fascioto-
mized patients (p50.0001). Sever does not consider
whether fasciotomy causes a secondary renal hit
through sudden reperfusion, or whether the patients
who required fasciotomy were more severely injured
in the first place. Comparing mortality rates: 16.4%
of the fasciotomized victims, and 13.9% of the non-
fasciotomized victims, died (p! 0.38).
Within the same group of victims, 121 amputa-
tions were performed on 98 patients of whom
30.5% died compared with 12.5% of the non-
amputated patients (p50.0001). Presence or
absence of amputations did not differ significantly
in the dialysed or non-dialysed victims (p! 0.78).
Sever et al. noted that fasciotomies were performed
solely on clinical indications and objective measures
were not used. Despite this, they conclude that
fasciotomies should only be performed if objective
measurements demonstrate a compartment pressure
to be within 30–40mmHg from the diastolic blood
pressure. They suggest conservative treatment with
mannitol first, which is also indicated in the initial
resuscitation protocols for the prevention of ARF.
A retrospective study performed after the Kobe
earthquake in 1995 followed up 42 patients with
crush injury, 2 years after the event (Matsuoka
et al., 2002). Fifty-eight lower extremities were
crushed. Twenty-two extremities in 17 patients
were fasciotomized. The patients in this group
were matched with patients treated conservatively
for age, sex, rates of ARF and percentage requiring
haemodialysis. Six legs of five patients required
radical debridement following fasciotomy. Infection
occurred at the fasciotomy site in three legs of two
patients. All patients were examined and graded for
muscle power and sensation to light touch and pin
prick. They concluded that fasciotomy failed to
improve limb function and radical debridement
further worsened functional outcome. Time to
rescue (duration of crushing) was shown to be an
independent predictor of overall muscle weakness.
Lower leg compartment syndrome more commonly
led to a severe disability than that in the thigh.
Anterior compartments were more susceptible to
damage than the posterior compartment.
Although their results highlight some useful
points, the authors do concede two potential flaws
in their non-randomised study. Firstly, intracom-
partmental pressures were not measured objectively
and, secondly, the initial severity of symptoms
between fasciotomized and non-fasciotomized
patients could not be compared retrospectively
and, if significantly different, may have influenced
the decision to perform fasciotomies in the first
place. They did note that the fasciotomized patients
were more severely injured and had a significantly
longer delay before rescue than the patients in the
non-fasciotomized group. Only seven out of 21
fasciotomized lower legs were fasciotomized within
24 h of insult and this delay may have caused the
poor outcomes in this group. Five patients with
severe disabilities following conservative treatment
were rescued within 10 h of injury and the authors
comment that fasciotomy may have improved
outcome in these patients (Matsuoka et al., 2002).
Matsuoka et al. conclude that fasciotomy does
not improve outcome, referencing one of their
previous studies to reinforce their point: Of 372
patients with crush syndrome, 12 patients out of 49
undergoing fasciotomy experienced surgical site
infections. Two patients died from sepsis and three
patients underwent amputation to control infection
(Matsuoka et al., 2002). Despite this, they still
advocate that a lower leg compartment showing
neurological deficit and raised compartment pres-
sures must be fasciotomized within 12 h.
Sheridan and Matsen demonstrate that normal
function returned in only 8% of patients who had
late fasciotomy over 12 h from the appearance of
motor weakness, pain on passive muscle stretch or
hypoaesthesia (Sheridan and Matsen, 1976).
Complication rates were also increased with late
fasciotomy. Meta-analysis has shown fasciotomy in
patients with paralysis to be unsatisfactory in over
80% of cases (Bradley, 1973). Models of total
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ischaemia suggest muscles and peripheral nerves can
survive for as long as 4 h without irreversible
damage but ischaemia for over 8 h does cause
irreversible damage.
Mubarak and Owen demonstrate that early
fasciotomy for patients with a postural crush
syndrome can have a good functional outcome
(Mubarak and Owen, 1975). Kurt et al. and
Williams et al. suggest fasciotomy for crush injury
should be done before 8–12 h after trauma to
minimise complications (Williams et al., 1997;
Kurt et al., 2003). The clinicians from Haifa
recommend fasciotomy within 6 h of developing
compartment syndrome but suggest it should be
contra-indicated when the muscle has died i.e., after
24 h (Reis and Michaelson, 1986; Reis and Better,
2005). They feel that an acute muscle crush
compartment syndrome has a different pathophys-
iology to compartment syndrome of other causes
and so should be treated differently. The major
difference is that crushed compartments invariably
contain dead muscle so prophylactic fasciotomy
should be contra-indicated to prevent sepsis.
Mannitol therapy in compartment syndrome
Mannitol has several beneficial effects in the man-
agement of crush syndrome, both systemically and
locally. As an osmotic diuretic, mannitol draws
extra-cellular oedema away from the tight fascial
compartment of the muscle, and promotes its
excretion through the kidneys. It is also positively
inotropic and reduces vascular permeability so
helping to stabilize the intravascular volume and
further reduce compartment pressures (Better et al.,
2003).
An experimental study from Israel on crush
injury induced in dog’s limbs, showed that mean
intracompartmental pressure decreased by 65% of
the original value in those given 20% mannitol
intravenously, compared to only 40% in the control
group injected with saline (p50.01) (Better et al.,
1991). Another canine study from Canada demon-
strated that muscle necrosis following reperfusion
could be significantly reduced by administration of
free-radical scavengers including mannitol (Walker
et al., 1987).
A case report, also from Israel, demonstrated that
a soldier with acute compartment syndrome and a
common peroneal neurapraxia was treated
successfully with mannitol therapy alone. The
cause of his compartment syndrome was heat
stroke and rhabdomyolysis from a 90 km march.
The heat stroke had fully resolved following alka-
line diuresis and diazepam 2 days before the
compartment syndrome developed. Leg circumfer-
ences were recorded but no compartment pressures
were measured in this case. The patient was
discharged with mild residual weakness 10 days
later. (Daniels et al., 1998).
Pain and paraesthesia from compartment syn-
drome can improve, and reduction in limb circum-
ference can occur, just 40min after administration
of mannitol, thus reducing or delaying the need for
fasciotomy (Better, 1999).
Mannitol preserves myocyte integrity by potently
scavenging oxygen free-radicals that destroy them
during reperfusion. Therefore, it prevents systemic
leakage of myoglobin, urate and phosphate, reduc-
ing the burden of these toxins to the kidney. The
systemic effects of mannitol and recommended
directions for use are discussed in Part 1: The
Systemic Injury.
Hyperbaric oxygen therapy
Hyperbaric oxygen therapy (HBO) has been
approved for use in treating crush injuries by the
Undersea and Hyperbaric Medical Society
(Feldmeier, 2003) and Medicare in the USA.
However, its use remains controversial.
When crush pressure is applied to a limb, the
energy dissipated by the injury causes a gradient of
tissue damage to occur (Buettner and Wolkenhauer,
2007). The zone directly at the site of injury is
frequently rendered nonviable regardless of inter-
vention. However, at a gradient from this area,
tissues are (variably) less injured but susceptible to a
self-perpetuating secondary injury from ischaemia.
The increased metabolic demand is directly depen-
dant on the integrity of the blood supply, and
indirectly dependent on developing oedema and
compartment syndrome. HBO’s main role is to
prevent this secondary injury and keep partially
injured tissue viable.
HBO increases the amount of oxygen physically
dissolved in plasma. At these concentrations, eryth-
rocyte oxygen carrying capacity is already satu-
rated. Hyperoxia is thought to have several
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beneficial effects on crushed limbs, and on ischae-
mic, traumatic wounds:
(1) The diffusion radius of HBO is four times
greater at 3 Absolute Atmospheres (ata) than
it is at sea level, supplying oxygen to under-
perfused tissue (Strauss, 2004; Buettner and
Wolkenhauer, 2007).
(2) Hyperoxia causes vasoconstriction, leading to a
reduction of blood flow by 20% and reduction
of capillary transudate and interstitial oedema
by 20% (Bird and Telfer, 1965; Bouachour
et al., 1996). The progression to compartment
syndrome is slowed, whilst the increased oxygen
dissolved in plasma compensates for the reduc-
tion in blood flow.
(3) HBO prevents neutrophils adhering to venules
during periods of ischaemia and reperfusion by
disrupting the b2 integrin system. This slows
production of oxygen free-radicals which pre-
vents a self-perpetuating secondary injury along
the injury gradient (Thom, 1993).
(4) HBO corrects pO2 to normal or slightly ele-
vated levels. This enhances neutrophils, osteo-
clasts and fibroblasts, facilitating phagocytic
killing of bacteria (Hunt and Pai, 1972; Hunt
et al., 1975).
(5) Hyperoxia is directly bactericidal to anaerobic
organisms (Bouachour et al., 1996).
(6) HBO enhances fibroblast differentiation, colla-
gen synthesis and angiogenesis, leading to
increased wound closure rates in hypoxic tissues
(Bouachour et al., 1996, Buettner and
Wolkenhauer, 2007).
Various clinical studies have supported these
mechanisms. In a blinded, randomized controlled
trial by Bouachor et al., "36 patients with severe
crush injury were given either hyperbaric oxygen or
placebo, immediately after initial surgical proce-
dures. Results showed complete wound healing in
94% of patients treated with hyperbaric oxygen,
compared to 59% in the placebo group. Higher
healing rates were proportional to levels of mea-
sured transcutaneous oxygen. Furthermore, repeat
surgical intervention was needed in only 6% of the
hyperbaric group compared with 33% in the
placebo group (Bouachor et al., 1996). They con-
cluded that HBO therapy is a useful adjunct in the
management of severe limb trauma in patients over
the age of 40 with a Gustillo grade III injury or
above (p50.05). For younger patients, results were
equivocal. However, they do show that HBO
improves wound healing by 35% and reduces
repetitive surgery rates for crushed limbs by 27%.
This is reinforced by a retrospective analysis of
crush injuries performed by Yildiz et al. following
the Marmara earthquake in 1999 (Yildiz et al.,
2004). The study followed 52 patients with com-
partment syndrome treated with fasciotomy and
then hyperbaric oxygen. Among these patients 45
recovered without any local or systemic sequelae.
Seven required dialysis for ARF and two of these
died during HBO therapy due to ARDS and sepsis.
Garcia-Covarrubias et al. performed a systematic
review of eight retrospective case series plus one
randomized controlled trial for the use of adjuvant
hyperbaric oxygen in management of crush injury
and acute, traumatic limb ischaemia (Garcia-
Covarrubias et al., 2005). Various conclusions
were drawn including that HBO is only beneficial
if administered early. HBO administered 16–18 hs
post injury is not effective. However, it was
suggested that surgery should not be delayed to
administer hyperbaric oxygen and fasciotomy
should remain the gold standard of care in acute
compartment syndrome. They called for further
prospective research to reinforce existing data.
Mathieu et al.’s research into HBO has revealed
that measurement of transcutaneous oxygen pres-
sures in ischaemic, traumatized limbs with non-
invasive electrodes, can reliably predict the final
outcome of the limb (Mathieu et al., 1990). Not only
can it evaluate the evolution of the traumatized limb
but they claim that it is possible to predict with 100%
sensitivity and 94% specificity whether or not sec-
ondary amputation should be performed. If HBO is
continued in these patients, mummification takes
place, demarcating viable from non-viable tissue
allowing focussed debridement and amputation as a
planned procedure (Loder, 1979; Bouachour et al.,
1996). Further validation of this technique may make
it a significant objective method of triaging trauma-
tized limbs. Current injury severity scoring systems
have limited usefulness to predict amputations (Bosse
et al., 2001; Garcia-Covarrubias et al., 2005).
Existing research focuses mainly on the ability of
HBO to facilitate wound healing and not on its
ability to treat compartment syndrome conserva-
tively. Several animal models have shown signifi-
cant reduction of oedema and muscle necrosis when
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HBO is used in crush injury and compartment
syndrome (Garcia-Covarrubias et al., 2005). Strauss
and Hart and Reis and Better have noted, in
separate series of patients with compartment syn-
drome treated with HBO, that none progressed and
none required fasciotomy (Strauss and Hart, 1989;
Reis and Better, 2005).
Similarly, Gold et al. report a case of compart-
ment syndrome resulting from envenomation from
a Diamondback rattlesnake that was successfully
treated conservatively using antivenom given
concomitantly with mannitol and HBO (Gold
et al., 2003). Objectively measured compartment
pressures improved, as did the patient’s pain and
paraesthesia.
Topical negative pressure therapy
Fasciotomy is still the gold standard of treatment
for compartment syndrome. If fasciotomy is to be
performed for an acute muscle-crush compartment
syndrome then all attempts to minimise infection
and improve wound healing should be taken.
Topical negative pressure (TNP) dressings applied
to fasciotomy wounds have several proven benefits.
Animal studies and humans trials have shown
that TNP therapy improves wound healing in a
variety of ways. Blood flow to injured tissues
markedly increases. Up to 5L of interstitial fluid
can be drawn off by the vacuum dressings daily
leading to a marked reduction in oedema (Argenta
and Morykwas, 1997). Bacteria are removed along
with tissue fluid and the localised vacuum creates a
hostile environment for potential infection. It has
also been shown that TNP dressings change the
cytoskeleton of cells within the wound, triggering a
cascade of intracellular signals that increases cellu-
lar mitosis and formation of granulation tissue
(Venturi et al., 2005).
Zannis et al. performed a retrospective analysis of
458 patients who underwent 804 fasciotomies over a
10-year period (Zannis et al., 2009). In the cohort
who had TNP dressings applied post-fasciotomy,
rates of delayed primary closure of wounds, as
opposed to reconstructive options, were higher
overall compared to the subgroup that had tradi-
tional wet-to-dry dressings. The time from fasciot-
omy to delayed primary closure was also
significantly shorter in the TNP therapy group.
Zannis concluded that the application of TNP
dressings reduces skin retraction and necrosis as
well as reducing muscle oedema permitting delayed
primary closure. Hospital stays are significantly
shortened and patients can be rehabilitated quicker.
In September 2009, the British Orthopaedic
Association (BOA) and the British Association of
Plastic, Reconstructive and Aesthetic Surgeons
(BAPRAS) produced a comprehensive review and
guidelines on the treatment of open tibia fractures
(Nanchahal et al., 2009). They recommend a com-
bined approach to treatment with appropriate
debridement followed by definitive flap closure as
early as possible, and at least within seven days of
injury. However, they also promote the use of TNP
therapy as the most appropriate form of temporary
dressing if flap closure is not possible at the time of
debridement and fracture fixation. They recognise
the beneficial affects on reducing oedema, infection
prevention and wound shrinkage, which may lead to
a reduced requirement, or size, of soft tissue
coverage. TNP therapy also prevents bone
desiccation.
The guidelines also promote the use of TNP
therapy following surgical wounds around closed
fractures, including fasciotomy wounds. Wounds
previously treated with TNP have a lower dehis-
cence rate following closure.
The same BOA/BAPRAS guidelines also pro-
mote the use of antibiotic-impregnated cement
beads placed locally into wounds to prevent infec-
tion. Both wound infection and osteomyelitis rates
are significantly reduced when beads are used as a
spacer for segmental bone loss. However, there is no
available data on whether beads and TNP used in
combination are even more beneficial, but they
conclude that this may be the case for patients with
heavy contamination or segmental bone loss
(Nanchahal et al., 2009).
A study on rabbits demonstrated that TNP
therapy applied to fasciotomy wounds following
crush injuries can significantly reduce the levels of
circulating serum myogblobin, compared with a
control group with normal dressings (p50.001)
(Morykwas et al., 2002). In turn, the progression to
myoglobinuric ARF and a systemic crush syndrome
are halted. There are also several anecdotal reports
to suggest that myoglobinuria and myoglobinaemia
from other causes, such as spider bites and electro-
cution injuries, improve much more rapidly than
expected if TNP therapy is used.
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Gastric pentadecapeptide BPC 157
New techniques and therapies are continually being
sought to improve healing of tissues following
injury. Damage to muscles, ligaments and tendons
is extremely common following sports injuries, and
rapid return of athletes to full fitness commands a
premium financial reward which can encourage new
research. Techniques such as gene therapy and
myoblast transplantation can help improve healing
times and reduce fibrosis and scar formation but are
expensive, complicated and inefficient (Novinscak
et al., 2008).
Several peptides are known to aid healing of
damaged tissues by interacting with the processes
of inflammation. Growth factors such as interleukin
1 (IL-1), tumour necrosis factor, transforming
growth factor beta, platelet-derived growth factor,
epidermal growth factor (EGF), insulin-like growth
factors and fibroblast growth factor (FGF) have
already been extensively investigated (Seiwerth
et al., 1997). Some have been shown to accelerate
wound healing in animal models but clinical use is
limited by the requirement of an effective carrier for
administration (Staresinic et al., 2003).
Researchers from the University of Zagreb in
Croatia have been investigating another potentially
useful agent, a gastric pentadecapeptide called BPC
157 (Sikiric et al., 1993a). It is a 15 amino acid
peptide isolated from gastric juice which is stable
without a carrier, can be administered topically in
a cream, or given intraperitoneally, intragastrically
or intrarectally diluted in saline or water (Sikiric
et al., 2003b). Animal models have been used
extensively to assess BPC 157’s ability to improve
wound healing and results have been extremely
encouraging.
The mechanism of action of BPC 157 appears to
be multifactorial but centred on its ability to increase
reticulin and collagen formation and organisation.
The early stages of inflammation are accelerated by
stimulation of angiogenesis and upregulation of
other growth factors by expression of Early
Growth Response 1 Gene (Mikus et al., 2001;
Ivetic Tkalcevic et al., 2007). Histological assess-
ments have demonstrated a clear time and dose-
dependent positive effect of BPC 157 on production
of granulation tissue by mononuclear inflammatory
cell infiltration (Staresinic et al., 2003).
Studies on burned mice show that topical appli-
cation of BPC 157 onto the burn wound prevents
occlusion of vessels with fibrin, reduces oedema and
necrosis, stimulates growth and proliferation of new
vessels and enhances re-epithelization (Mikus et al.,
2001). The new skin has a relatively increased tensile
strength compared to controls. Local absorption
of BPC 157 through the burnt skin also led to
accelerated healing of gastric stress ulcers caused by
the burn. They postulated the mechanism to involve
modulation of systems involving nitric oxide, dopa-
mine and adrenal hormones (Sebecic et al., 1999).
Human clinical trials are currently being con-
ducted to determine BPC 157’s effectiveness for
treating inflammatory bowel disease (Veljaca et al.,
2003; Ruenzi et al., 2005; Vuksic et al., 2007).
Studies on rats have also demonstrated accelerated
healing of bowel anastomoses, peptic ulcer disease
and various lesions within liver, pancreas, cardiac
muscle and corneas (Seiwerth et al., 1997; Sebecic
et al., 1999; Sikiric et al., 2003b).
Further animal studies have investigated the use
of BPC 157 on the musculoskeletal system, includ-
ing muscle contusions, tendon transections, nerve
crush injuries and muscle-crush injuries. A study by
Sebecic et al. discovered that injection of BPC 157
either subcutaneously or intramuscularly into the
limbs of rabbits with segmental bone loss stimulated
osteogenesis (Sebecic et al., 1999). Callus formation
was measured on plain radiographs and bone was
analysed histologically and with microphotodensi-
tometry. Rates and quality of callus formation
doubled and results were comparable to rabbits
treated with autologous bone marrow injection.
Control groups treated with intramuscular injection
of saline frequently went on to non-union. They
infer that the development of osteoporosis and
increased fracture risk in humans that is known to
occur following gastrectomy could be due to
reduced levels of BPC 157.
Similarly, administration of BPC 157 either
locally or systemically promotes healing of tran-
sected Achilles tendon and quadriceps muscle in rats
(Staresinic et al., 2003; Krivic et al., 2006; Staresinic
et al., 2006; Krivic et al., 2008). In particular it is
noted that the original structure and function of the
transected tissue is restored by stimulation of
tenocyte and myocyte growth, longitudinal collagen
deposition and reduction in fibrosis. The reduction
in connective tissue scarring is thought to permit a
more suitable environment for myotubules to grow,
and induction of cytokines and growth factors
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stimulate early extracellular matrix (collagen) for-
mation. BPC 157 also promotes axon regeneration
in transected rat sciatic nerves that have been
re-anastomosed (Gjurasin et al., 2003).
The rat gastrocnemius muscle complex was used
by the Zagreb University researchers as a repro-
ducible model for major muscle crush injury
(Novinscak et al., 2008). Effectiveness of both
systemic and topical administration of BPC 157
was evaluated functionally, macroscopically, micro-
scopically and immunohistochemically by blinded
observers. Serum enzyme levels were also measured.
All rats treated with BPC 157 had earlier muscle
regeneration and almost no scar formation. An
advanced healing course was noted, even after the
first application. Oedema was markedly reduced,
injury severity scores were reduced and post-injury
contractures were reduced with improved walking
and muscle function. The numbers of inflammatory
cells and regenerating myofibres were increased.
Myofibre diameter was also increased with more
centralised nuclei and increased desmin production.
Consistent with BPC 157 promotion of healing in
other tissues, it was also noted that substantial
angiogenesis and regeneration of intramuscular
neurons occurred. Serum CK levels were signifi-
cantly reduced in the BPC 157 treated group, which
infers that rhabdomyolysis, and subsequent pro-
gression to a systemic crush syndrome, are reduced
or prevented.
Both intestinal absorption and local blood supply
to muscle can be severely limited following crush
injuries. Major advantages of BPC 157 over other
peptides are its stability as an independent com-
pound and its effectiveness when applied topically
and in low doses. Despite over two decades of
extensive trials using BPC 157, no adverse side
effects have been discovered and a lethal dose has
never been reached (Veljaca et al., 2003; Ruenzi
et al., 2005).
Discussion
Crush injuries are uncommon in British civilian life
but can occur as epidemics in areas following
natural disasters or war. The systemic effects of
the crush syndrome can be prevented and reversed
with early intensive treatment as discussed in Part 1:
The Systemic Injury. Surgeons are increasingly
required to salvage maximal function from crushed
limbs.
The pathophysiology of muscle damage in crush
injuries is now better understood. Mannitol therapy
should be an essential component of initial resusci-
tation to prevent, or treat, the systemic effects of
crush syndrome. Due to its ability to reduce limb
oedema and improve myocyte integrity, mannitol
also helps reduce compartment pressures and
improve limb function, occasionally enough to
avoid fasciotomy.
To gain maximum benefit from Mannitol therapy
it should be administered just prior to, or soon after,
release of the crushing force when free radical
production is at its greatest. Unfortunately, this is
rarely possible in clinical practice. However, com-
partment syndrome may cause a secondary crush
syndrome; so early administration of Mannitol
should help prevent ARF, reduce limb swelling
and avoid sequelae from this secondary hit.
Pre-extrication administration of free-radical
scavengers, calcium influx blockers, potassium
binders and large volumes of crystalloid could
minimise the damaging effects of the reperfusion
syndrome. This may add support to the controver-
sial practice of applying tourniquets before limb
extrication to buy time until appropriate medical
care is available. However, there are no studies on
humans or animals that prove these theoretical
benefits and tourniquet use has its own complica-
tions as discussed in Part 1: The Systemic Injury.
Until further research is performed, we advocate
reserving use of pre-hospital tourniquets to control
catastrophic haemorrhage only as per the UK
Defence Medical Services haemostasis ladder
(Figure 1, Part 1).
There is a wealth of evidence that suggests HBO
is useful as an adjunct to fasciotomy in crush
syndromes, especially in the over 40 year old patient
with pre-existing ischaemic pathologies (Bouachour
et al., 1996; Strauss, 2002; Garcia-Covarrubias
et al., 2005; Buettner and Wolkenhauer, 2007).
There is also growing evidence to suggest that it
could be used as a conservative alternative to it, but,
to date, there are no direct comparative studies for
treating acute muscle crush compartment syndrome.
Useful prospective, comparative studies between
multiple crush victims are limited due to the
technical difficulties and cost of global equipment
transportation following mass disasters. It has been
Crush injuries and crush syndrome. Part 2 143
Trauma 2010; 12: 133–148
suggested that HBO therapy would pay for itself
financially when compared to the cost of treating
crushed patients with fracture non-unions (Buettner
and Wolkenhauer, 2007). However, HBO’s sparse
availability and the sporadic, unpredictable nature
of crush injury epidemics, make HBO therapy a less
feasible treatment option in most areas of the world.
It is clear that functional recovery from fasciot-
omy is dependent on the residual viable muscle and
peripheral nerve within a compartment. This seems
to be inversely proportional to the severity of initial
insult and time delay to fasciotomy. Early fasciot-
omy and debridement of necrotic muscle improves
survival of remaining viable tissue whereas delayed
fasciotomy exposes necrotic, unsalvageable tissue to
severe haemorrhage and infection. There seems to
be consensus that fasciotomy should be contra-
indicated from 12–24 h following onset of compart-
ment syndrome symptoms of pain on passive muscle
stretch or paraesthesia. There is also consensus on
the need for aggressive surgical debridement of open
traumatic wounds along with fasciotomy if indi-
cated. Closed crush injuries with absent pulses
should also be urgently decompressed. However,
there is still debate as to the role of fasciotomy in
closed crush injuries with adequate distal vascular
supply. If conservative measures to reduce limb
swelling can be employed before pulses are lost then
the cascade of worsening compartment syndromes
may be halted and limb function salvaged.
Radical debridement of necrotic tissue, although
necessary if fasciotomy is undertaken, produces the
worst functional outcome. Attempts to quantify the
ratio of viable to non-viable muscle and nerve may
help to decide whether or not to perform a
fasciotomy. Simple clinical evaluation of muscle
activity and sensation to light touch or pin prick can
be quickly and easily performed at the bedside and
may influence a decision.
Despite some pre-hospital teachings, field fascio-
tomies should not be performed on crushed limbs
(Schultz and Koenig, 1997). The exposure of dead
muscle that cannot be adequately debrided would
render the patient susceptible to uncontrolled
haemorrhage and sepsis. These risks far outweigh
the functional benefits of early fasciotomy. The
decision to fasciotomize should be made by expe-
rienced clinicians in a definitive care centre with
adequate sterile surgical facilities and appropriate
intensive, multi-disciplinary care backup
(Kurt et al., 2003). Despite these measures, sepsis
remains one of the leading causes of mortality from
crush injuries (Kazancioglu et al., 2002).
There is overwhelming evidence to support the
use of TNP therapy on traumatic wounds and
fasciotomy wounds. Skin retraction, infection rates
and the requirement for surgical reconstructive
options are all vastly reduced. Animal models of
crush injuries, and several anecdotal reports, sug-
gest that TNP therapy applied post-fasciotomy can
reduce myoglobinuric ARF and progression to the
crush syndrome. Proponents of non-surgical man-
agement of acute muscle-crush compartment syn-
drome, such as the clinicians in Haifa, Israel, who
have published extensively on the topic, and some
members of the International Renal Disaster Relief
Task Force have, so far, not mentioned the use of
TNP therapy. It would be interesting to observe any
experiences they gain with TNP for treating
fasciotomy wounds following crush injuries.
Novel therapies for treating musculoskeletal
injuries are continually being sought. BPC 157 has
been extensively researched in Croatia for the last
two decades. Extremely promising results have been
published demonstrating accelerated healing of
many tissue types with minimal scarring. For
crush injuries, BPC 157 applied topically as a
cream has been shown to reduce oedema, rhabdo-
myolysis and contractures, and encourage angio-
genesis and myocyte and nerve regeneration.
Functional results are excellent and no harmful
side effects have been found. Human trials are being
conducted for its use in treating inflammatory
bowel disease. Similar human trials and interna-
tional validation of their existing studies would be
essential before being commercially manufactured.
BPC 157 appears to be stable without need for a
carrier, is effective in low doses and effective when
administered topically, orally, rectally, intramuscu-
larly and intraperitoneally. This suggests its clinical
applications would be far reaching. Storage and
international transportation to mass disaster areas
for treatment of crush injuries would also be much
simpler and cheaper compared with dialysis, HBO
or TNP equipment. However, neither the cost of
BPC 157 nor the difficulty of production on a mass
scale has ever been discussed in the literature.
Despite surgical or conservative interventions,
crush injuries can irreversibly destroy limb function.
Advances in reconstructive surgical techniques and
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prosthetics have provided clinicians with a whole
host of viable options for rehabilitating patients.
Reconstructive surgery is usually only undertaken
after primary repair procedures of debridement,
skeletal stabilization and emergency skin cover
(Weinand et al., 2000) and also once oedema has
settled (Asgari and Spinnelli 2000). An early com-
bined approach involving a reconstructive surgeon
in the primary stabilising procedure can ensure that




# Crushed patients in Britain should be extricated
and transferred to definitive medical care as
swiftly as possible.
# Acute limb amputations should be avoided unless
extrication is impossible by any other means or
limb sepsis threatens life.
# Aggressive fluid resuscitation should be started
peri-extrication if possible.
# Advanced Life Support protocols (ATLS",
Trauma Manual or the military Battlefield equiv-
alent) should be followed.
# Alkaline diuresis and mannitol therapy should be
commenced as soon as intensive monitoring is
available.
# Continued resuscitative attempts should involve a
multi-disciplinary approach with intensivists,
nephrologists, orthopaedic and reconstructive
surgeons.
# Compartment syndromes should be treated with
fasciotomy, debridement of non-contractile tissue
and TNP dressings as early as possible and
preferably within 6–12 h of symptoms developing.
# Fasciotomies should not be performed in crushed
limbs if a compartment syndrome has been
present for more than 24 h. Instead, functional
outcomes of limbs should be improved with
physio- and occupational therapy, reconstructive
surgery, prosthetics, arthrodeses and amputations
if other methods fail.
# HBO therapy may also be beneficial if immedi-
ately available but further clinical trials would be
useful.
# And finally, BPC 157 should be thought of as a
novel ‘wonder-cream’ with extremely promising
early results, but, unfortunately, a long way off
from being commercially available.
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